Dublin, April 13, 2026 (GLOBE NEWSWIRE) -- The "Oncolytic Virus - Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering.
This comprehensive report offers detailed insights into over 100 companies and 110 drugs within the oncolytic virus field. It provides a thorough assessment of therapeutics by product type, development stage, route of administration, and molecule type, along with an evaluation of inactive pipeline products.
Oncolytic viruses (OVs) stand out as an innovative category of cancer therapeutics that selectively target and replicate in tumor cells, driving immunogenic cell death and activating antitumor immunity. These viruses are being extensively studied across 100 clinical trials to determine their efficacy both alone and when combined with other cancer therapies.
OVs are adept at converting immunologically "cold" tumors into inflamed sites, aiding in immune-mediated tumor clearance. These agents can be administered in various ways, including intratumorally and intravenously, and are generally well tolerated. Their genetic engineering allows precise modification to enhance tumor specificity and immune activation.
Company and Product Profiles
Shanghai Sunway Biotech
Product: Oncorine
Oncorine, developed by Shanghai Sunway Biotech, is a genetically modified adenovirus approved for nasopharyngeal carcinoma treatment. It has paved the way for the further development of cancer immunotherapy.
Candel Therapeutics
Product: CAN-2409
CAN-2409 facilitates individualized immune responses by delivering the HSV-tk gene to tumors and is progressing through Phase III trials for prostate cancer.
Binhui Biopharmaceutical
Product: OH2
Binhui's OH2, an oncolytic herpes simplex virus, targets melanoma and is in Phase III trials, focusing on enhancing antitumor immune responses.
EpicentRx
Product: AdAPT-001
AdAPT-001 combines with checkpoint inhibitors to enhance responses in sarcoma and refractory solid tumors, now in Phase II development.
Converd
Product: CVD-1301.V01
CVD-1301.V01, an oncolytic vaccinia virus by Converd, is undergoing Phase II trials for pancreatic cancer, emphasizing cancer system immunotherapy.
Imugene
Product: VAXINIA (CF33-hNIS)
This innovative DNA vaccinia virus targets a range of solid tumors, in Phase I stage for GI malignancies.
This report offers a meticulous commercial assessment of oncolytic virus therapies, including collaborations, agreements, and licensing deals, crucial for understanding the current and emerging trends in cancer therapy. It evaluates competitive landscapes, company profiles, and market dynamics, providing a detailed overview of ongoing and upcoming innovations in the field.
Report Highlights
- In November 2025, Imugene Ltd and JW Therapeutics initiated a collaboration to explore a combined cancer treatment strategy involving Imugene's oncolytic virus CF33-CD19 and JW's CAR-T therapy for advanced solid tumors.
- Calidi Biotherapeutics gained Fast Track designation for CLD-201 (SuperNova), targeting soft tissue sarcoma with an adipose stem-cell loaded oncolytic virus.
- Oncolytics Biotech highlighted pelareorep's potential in stimulating anti-tumor immunity in pancreatic ductal adenocarcinoma (PDAC).
- Candel Therapeutics received RMAT designation for CAN-2409, an immunotherapy for localized prostate cancer, also granted Fast Track designation.
- Hangzhou ConVerd's oncolytic vaccinia virus product, hV01, is undergoing a Phase IIa study for sarcoma and recurrent cervical cancer treatment.
Companies Featured
- Shanghai Sunway Biotech
- Oncolytics Biotech
- SillaJen
- Candel Therapeutics
- Binhui Biopharmaceutical
- Oryx GmbH
- Oncolys Biopharma
- EpicentRx
- Theriva Biologics
- Lokon Pharma
- DNAtrix
- Surv BioPharma Inc.
- Treovir
- Immvira Pharma
- Virogin Biotech
- OrienGene Biotechnology
- Apices Soluciones
- Vyriad
- Transgene
- BioEclipse Therapeutics
- Imugene
For more information about this report visit https://www.researchandmarkets.com/r/twiwj3
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
